Biogen Inc. (BIIB) Stake Raised by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 24.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,644 shares of the biotechnology company’s stock after buying an additional 23,418 shares during the period. Temasek Holdings Private Ltd owned 0.06% of Biogen worth $37,150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Carroll Financial Associates Inc. raised its holdings in shares of Biogen by 1.2% during the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 6 shares during the last quarter. New Amsterdam Partners LLC NY raised its holdings in Biogen by 0.8% during the second quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 11 shares in the last quarter. Alta Capital Management LLC raised its holdings in Biogen by 0.8% during the second quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 15 shares in the last quarter. Bienville Capital Management LLC raised its holdings in Biogen by 2.2% during the second quarter. Bienville Capital Management LLC now owns 880 shares of the biotechnology company’s stock worth $239,000 after purchasing an additional 19 shares in the last quarter. Finally, Forbes J M & Co. LLP raised its holdings in Biogen by 0.6% during the second quarter. Forbes J M & Co. LLP now owns 3,121 shares of the biotechnology company’s stock worth $846,000 after purchasing an additional 19 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

In other news, Director Alexander J. Denner acquired 30,000 shares of the stock in a transaction on Wednesday, November 29th. The shares were purchased at an average cost of $317.36 per share, for a total transaction of $9,520,800.00. Following the transaction, the director now owns 10,029 shares in the company, valued at approximately $3,182,803.44. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.25% of the company’s stock.

Biogen Inc. (BIIB) opened at $319.87 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. The stock has a market cap of $67,122.77, a P/E ratio of 14.70, a price-to-earnings-growth ratio of 1.98 and a beta of 0.73. Biogen Inc. has a 12-month low of $244.28 and a 12-month high of $348.84.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.19 earnings per share. equities analysts forecast that Biogen Inc. will post 22.03 EPS for the current year.

BIIB has been the topic of several recent analyst reports. SunTrust Banks initiated coverage on Biogen in a report on Wednesday, September 20th. They set a “buy” rating and a $360.00 target price on the stock. Vetr cut Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 target price on the stock. in a report on Tuesday, August 29th. Stifel Nicolaus raised Biogen from a “hold” rating to a “buy” rating and boosted their target price for the stock from $300.00 to $415.00 in a report on Tuesday, October 17th. Mizuho raised Biogen from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $319.00 to $400.00 in a report on Tuesday, October 17th. Finally, Morgan Stanley reissued a “buy” rating on shares of Biogen in a report on Tuesday, October 17th. Twelve research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Biogen currently has an average rating of “Buy” and a consensus target price of $344.60.

TRADEMARK VIOLATION WARNING: “Biogen Inc. (BIIB) Stake Raised by Temasek Holdings Private Ltd” was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/12/06/biogen-inc-biib-stake-raised-by-temasek-holdings-private-ltd.html.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

What are top analysts saying about Biogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biogen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit